【产品介绍】：

产品名称 LY2228820 英文名称 LY2228820 应用 A p38 MAP Kinase inhibitor with IC50 of 70nM 规格或纯度 ≥98% 别名 LY 2228820;LY-2228820 英文别名 Ralimetinib dimesylate；LY2228820 dimesylate;LY2228820 2MsOH;LY 2228820;LY-2228820；5-[2-(tert-Butyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate 运输条件 超低温冰袋运输 生化机理 SB 202190 is a p38 MAP (mitogen activated protein) Kinase inhibitor with an IC50 of 7 nm. LY2228820 inhibits lipopolysaccharide (LPS)-induced TNFα formation in murine peritoneal macrophages, with IC50 of 5.2 nM. In multiple myeloma (MM) cells, LY2228820 significantly blocks p38MAPK signaling, as revealed by its inhibition on phosphorylation of HSP27, a downstream target of p38MAPK, without affecting the expression level of HSP27. LY2228820 enhances bortezomib-induced cytotoxicity and apoptosis, but it alone doesn't inhibit the growth of MM.1S cells. LY2228820 also inhibits secretion of IL-6 and MIP-1α in long-term BM stromal cells (LT-BMSCs), BM mononuclear cells (BMMNCs), peripheral blood (PB) CD138+, CD138? or PB CD14+ cells. LY2228820 also blocks osteoclastogenesis from CD14+ cells.LY 2228820 is a novel and potent p38 MAPK inhibitor with potent anti-inflammatory activity.\xa0It significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs.CAS编号 862507-23-1 溶解性 DMSO ≥33mg/mL Water ≥121mg/mL Ethanol ≥2.6mg/mL 储存温度 -20°C储存 分子量 612.74 分子式 C26H37FN6O6S2 PubChem CID 11570805